SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-093965
Filing Date
2023-04-06
Accepted
2023-04-06 16:06:02
Documents
12
Period of Report
2023-04-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d319600d8k.htm   iXBRL 8-K 21512
  Complete submission text file 0001193125-23-093965.txt   138727

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lrmr-20230403.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lrmr-20230403_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lrmr-20230403_pre.xml EX-101.PRE 10816
6 EXTRACTED XBRL INSTANCE DOCUMENT d319600d8k_htm.xml XML 3236
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 23806201
SIC: 2834 Pharmaceutical Preparations